Skip to main content
. Author manuscript; available in PMC: 2023 Jan 15.
Published in final edited form as: Clin Cancer Res. 2022 Jul 15;28(14):3042–3052. doi: 10.1158/1078-0432.CCR-21-4499

Figure 1. Consort diagram for patients who underwent TIL harvest with intent to treat on three consecutive TIL ACT treatment protocols.

Figure 1.

Patients who were treated on earlier protocols were excluded given more variability in the lymphodepletion regimen and less availability of tumor and infusion product. Patients who received pembrolizumab as part of the treatment regimen were included in the cohort.